Qualigen Therapeutics (AIXC) Stock Price, News & Analysis

Company Overview

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key Stats

• Today's Range: $1.25 to $1.47
• 50-Day Range: $1.06 to $1.57
• 52-Week Range: $0.92 to $8.81
• Volume: 100,185 shs
• Average Volume: 39,529 shs
• Market Capitalization: $27.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Qualigen Therapeutics Stock Analysis - MarketRank™

Qualigen Therapeutics scored higher than 6% of companies evaluated by MarketBeat, and ranked 74th out of 80 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Qualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Qualigen Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Qualigen Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qualigen Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Qualigen Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.44% of the float of Qualigen Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Qualigen Therapeutics has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qualigen Therapeutics has recently decreased by 24.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Qualigen Therapeutics does not currently pay a dividend.

Dividend Growth

Qualigen Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Qualigen Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.17% of the stock of Qualigen Therapeutics is held by insiders.

Percentage Held by Institutions

3.18% of the stock of Qualigen Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AIXC
• CIK: 1460702
• Web: N/A
• Phone: (760) 918-9165
• Fax: 760-918-9127
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($6.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -771.52%
• Return on Assets: -79.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.57
• Quick Ratio: 11.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 1.70

Miscellaneous

• Outstanding Shares: 20,240,000
• Free Float: 19,998,000
• Market Cap: $27.93 million
• Optionable: N/A
• Beta: 0.52